AH Bio Fund IV, L.P.
CIK: 0001889476
Transaction Breakdown
Open Market Buys (P)1 (50.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (50.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
BRVE
Braveheart Bio, Inc.
10% Owner
Discretionary Trading P&L
Holdings
About AH Bio Fund IV, L.P.
AH Bio Fund IV, L.P. (SEC CIK 0001889476) files insider reports with the SEC as 10% Owner of Braveheart Bio, Inc. (BRVE).
Signal8 holds 2 ownership filings by AH Bio Fund IV, L.P. (1 Form 3, 1 Form 4), filed between Aug 5, 2026 and Aug 11, 2026. Those filings report 2 transactions, the latest on Aug 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on AH Bio Fund IV, L.P.'s filings is in MENLO PARK, CA.
Recent filings by AH Bio Fund IV, L.P.
Other insiders filing for Braveheart Bio, Inc. (BRVE)
- Agarwala Vineeta, Director
- Chimovits Erez, Director
- ORBIMED ADVISORS LLC, Director
- Jiangsu Hengrui Pharmaceuticals Co., Ltd., 10% Owner
- Forbion Growth Opportunities Fund III Cooperatief U.A., 10% Owner
- Rickey James Paul, Chief Financial Officer